Why the study?
Cardiovascular toxicity from immune checkpoint inhibitors has received less attention despite increasing reports of fatal heart failure and myocarditis.
What are the cardiac adverse effects of immune checkpoint inhibitors in cancer patients?
What are the cardiac adverse effects of immune checkpoint inhibitors in cancer patients?
This review highlights the critical need for awareness and monitoring of severe cardiac toxicities, such as myocarditis and heart failure, associated with immune checkpoint inhibitor therapy in cancer patients.
Alerts clinicians to monitor for ICI myocarditis and fatal HF; leaves open prospective studies on incidence and prevention.
The immune checkpoint molecules are involved in the regulation of T cells in order to prevent them from attacking to sell tissues and play a role in the immune response homeostasis. Application of the immune checkpoint inhibitors (ICIs) has provided a promising therapeutic approach in pathologies where the immune system is suppressed. The extended utilization of ICIs in several cancers has caused immune-related side effects in the cardiovascular system like cardiomyopathy and myocarditis. Cardiac toxicity, one of the main side effects of the ICIs-based therapeutic approach, has less been concerned; however, during the last years, many cases of fatal heart failure and myocarditis have been reported in patients treated with ICIs. In this review article, we attempted to discuss the cardiac adverse effects of inhibiting different immune checkpoint molecules.
No takes yet. Share an insight, caveat, or question.
Behravesh et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: